Advanced neuroendocrine prostate tumors regress to stemness.

Leigh Ellis and Massimo Loda Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263; Department of Medical Oncology, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana–Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, MA 02115; Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, MA 02115; and Division of Cancer Studies, King’s College London, London SE1 9RT, United Kingdom